Jane Street
TEVA icon

Jane Street’s Teva Pharmaceuticals TEVA Stock Holding History

Jane Street’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.3M Sell
738,800
-646,800
-47% -$20.8M ﹤0.01% 1690
2025
Q4 		$43.2M Sell
1,385,600
-1,328,700
-49% -$32.7M 0.01% 1040
2025
Q3 		$54.8M Sell
2,714,300
-869,000
-24% -$15.3M 0.01% 907
2025
Q2 		$60.1M Buy
3,583,300
+1,798,500
+101% +$29M 0.01% 664
2025
Q1 		$27.4M Buy
1,784,800
+344,500
+24% +$6.15M 0.01% 1053
2024
Q4 		$31.7M Buy
1,440,300
+310,100
+27% +$5.64M 0.01% 941
2024
Q3 		$20.4M Buy
1,130,200
+426,000
+60% +$7.46M ﹤0.01% 1230
2024
Q2 		$11.4M Sell
704,200
-812,800
-54% -$12.5M ﹤0.01% 1881
2024
Q1 		$21.4M Buy
1,517,000
+69,400
+5% +$875K ﹤0.01% 1134
2023
Q4 		$15.1M Buy
1,447,600
+176,100
+14% +$1.64M ﹤0.01% 1532
2023
Q3 		$13M Sell
1,271,500
-74,000
-5% -$689K ﹤0.01% 1503
2023
Q2 		$10.1M Sell
1,345,500
-82,800
-6% -$671K ﹤0.01% 1889
2023
Q1 		$12.6M Buy
1,428,300
+74,900
+6% +$741K 0.01% 1402
2022
Q4 		$12.3M Sell
1,353,400
-1,586,100
-54% -$13.8M 0.01% 1415
2022
Q3 		$23.7M Sell
2,939,500
-473,300
-14% -$4.19M 0.01% 937
2022
Q2 		$25.7M Buy
3,412,800
+1,718,900
+101% +$15M 0.01% 935
2022
Q1 		$15.9M Sell
1,693,900
-275,400
-14% -$2.3M 0.01% 1481
2021
Q4 		$15.8M Sell
1,969,300
-954,000
-33% -$8.61M 0.01% 1394
2021
Q3 		$28.5M Buy
2,923,300
+722,100
+33% +$6.76M 0.01% 894
2021
Q2 		$21.8M Buy
2,201,200
+842,700
+62% +$8.92M 0.01% 1018
2021
Q1 		$15.7M Sell
1,358,500
-281,100
-17% -$3.22M 0.01% 1177
2020
Q4 		$15.8M Buy
1,639,600
+613,900
+60% +$5.88M 0.01% 1038
2020
Q3 		$9.24M Buy
1,025,700
+135,000
+15% +$1.43M 0.01% 1282
2020
Q2 		$11M Sell
890,700
-832,500
-48% -$9.42M 0.01% 1126
2020
Q1 		$15.5M Buy
1,723,200
+1,644,100
+2,079% +$16.8M 0.02% 551
2019
Q4 		$775K Sell
79,100
-124,300
-61% -$1.11M ﹤0.01% 3129
2019
Q3 		$1.4M Buy
203,400
+178,100
+704% +$1.36M ﹤0.01% 2199
2019
Q2 		$234K Sell
25,300
-11,400
-31% -$137K ﹤0.01% 4523
2019
Q1 		$575K Sell
36,700
-187,200
-84% -$3.3M ﹤0.01% 3516
2018
Q4 		$3.45M Sell
223,900
-45,500
-17% -$933K 0.01% 1204
2018
Q3 		$5.8M Buy
269,400
+201,800
+299% +$4.68M 0.01% 930
2018
Q2 		$1.64M Sell
67,600
-101,400
-60% -$2.07M ﹤0.01% 2173
2018
Q1 		$2.89M Buy
169,000
+28,800
+21% +$562K 0.01% 1454
2017
Q4 		$2.66M Buy
140,200
+48,300
+53% +$727K 0.01% 1323
2017
Q3 		$1.62M Buy
91,900
+72,100
+364% +$1.62M 0.01% 1796
2017
Q2 		$658K Sell
19,800
-20,200
-51% -$625K ﹤0.01% 2689
2017
Q1 		$1.28M Sell
40,000
-124,300
-76% -$4.24M 0.01% 1795
2016
Q4 		$5.96M Buy
164,300
+132,200
+412% +$5.28M 0.03% 563
2016
Q3 		$1.48M Buy
32,100
+15,900
+98% +$830K 0.01% 1517
2016
Q2 		$814K Buy
16,200
+7,400
+84% +$394K ﹤0.01% 2220
2016
Q1 		$471K Sell
8,800
-9,900
-53% -$581K ﹤0.01% 2676
2015
Q4 		$1.23M Buy
+18,700
New +$1.16M 0.01% 1538
2015
Q2 		– Sell
-7,400
Closed -$461K – 4039
2015
Q1 		$461K Buy
7,400
+3,900
+111% +$227K ﹤0.01% 2126
2014
Q4 		$201K Buy
+3,500
New +$195K ﹤0.01% 2228

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street's TEVA Position: Q1 2026 in Review

Jane Street reduced its Teva Pharmaceuticals (TEVA) stake by 9.5% in Q1 2026, selling an estimated $4.96M and leaving 1,464,638 shares worth $44.1M. The position accounts for 0.01% of the portfolio, ranked #1147.

Jane Street first reported a position in TEVA in Q4 2013 and has held it in 49 quarters since. The position peaked at $60.7M in Q3 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Jane Street held 1,464,638 shares of Teva Pharmaceuticals worth $44.1M as of Q1 2026.
  • Jane Street sold 154,241 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.96M.
  • Teva Pharmaceuticals made up 0.01% of Jane Street's portfolio in Q1 2026, its #1147 holding.
  • Jane Street first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Jane Street's Teva Pharmaceuticals position peaked at $60.7M in Q3 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.